We invest in creating better health outcomes.

Suren Ajjarapu

Chairman of the Board and Chief Executive Officer

Mr. Ajjarapu has served as Chairman of the Board, Chief Executive Officer and Secretary since our acquisition of Trxade Group, Inc., a Nevada corporation (“TRxADE Nevada”) (our predecessor company) on January 8, 2014, and as the Chairman of the Board, Chief Executive Officer and Secretary of TRxADE Nevada since its inception. Mr. Ajjarapu is also Chief Executive Officer of Aesther Healthcare Acquisition Corp., a Special Purpose Acquisition Company traded on Nasdaq under the symbol “AEHA”, as well as a director of Oceantech Acquisition I Corp., traded on Nasdaq under the symbol “OTECU”. Mr. Ajjarapu was a Founder, CEO and Chairman of Sansur Renewable Energy, Inc., a company involved in developing wind power sites in the Midwest, United States, from 2009 to 2012. Mr. Ajjarapu was a Founder, President and Director of Aemetis, Inc., a biofuels company (AMTX.OB) and a Founder, Chairman and Chief Executive Officer of International Biofuels, a subsidiary of Aemetis, Inc., from 2006 to 2009. Mr. Ajjarapu was Co-Founder, COO, and Director Global Information Technology, Inc., an IT outsourcing and systems design company, headquartered in Tampa, Florida with major operations in India from 1995 to 2006. Mr. Ajjarapu holds an MS in Environmental engineering from South Dakota State University, Brookings, South Dakota, and an MBA from the University of South Florida, specializing in International Finance and Management. Mr. Ajjarapu is also a graduate of the Venture Capital and Private Equity program at Harvard University.

Prashant Patel

President and Chief Operating Officer

Mr. Patel has served as our full-time President and COO, and as a director, since our acquisition of TRxADE Nevada on January 8, 2014. Mr. Patel is a registered pharmacist and pharmaceutical consultant with over twenty years of experience in retail pharmacy and pharmaceutical logistics, and the founder of several pharmacies in the Tampa Bay, Florida area. Since October 2008, Mr. Patel has been Managing Member of APAA LLC, a pharmacy and CEO of Pharmaceutical Returns Of America LLC, a pharmaceutical reverse distributor. Mr. Patel graduated from Nottingham University School of Pharmacy and practiced in the UK before obtaining his masters in Transport, Trade and Finance from Cass Business School, City University, UK.

Eric Sherb

Chief Financial Officer

Eric is a CPA with 15 years experience in accounting advisory, auditing and mergers and acquisitions. He began his career at PricewaterhouseCoopers and has several years experience in mid‐size audit and consulting firms with clients in a variety of industries. Eric has extensive experience in financial reporting for pre‐revenue startups to large public entities, including bookkeeping, consolidation, financial statement preparation and analysis, management and investor reporting, financial modeling and audit and IPO readiness. Eric has provided technical advisory on complex transactions, including debt/equity financings, business combinations, revenue recognition, lease arrangements, etc. Eric has helped clients establish and improve financial operations, including system implementation, compensation structures and the creation of accounting policies and processes. Eric graduated with a BBA from Emory University in Accounting and Finance.

Shankar Hariharan, Ph.D.

Founder & Chief Executive Officer

Dr. Hariharan is the Founder, President, and CEO of Scienture, Inc. Dr. Hariharan has over 35 years of experience in successfully leading branded, specialty, and generic pharmaceutical businesses and has held several leadership positions at Forest Labs, Par Pharmaceuticals, and Amneal Pharmaceuticals.

As the Executive Vice President and chief scientific officer at Amneal, he oversaw Global Research and development, Global Regulatory Affairs, and Specialty Product Development. He was instrumental in achieving significant revenue growth (>$1.5B) with high profit margins.

Before joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in new molecule discovery and product development for key indications in Dermatology, leading to the company’s successful acquisition.

Some notable blockbuster drug products, offering unique value to patients and caregivers, brought to market under Dr. Hariharan’s leadership include Celexa® (>$2B), Lexapro® ($ 4B), Namenda® (>$2B), Megace ES® (>$100M) and over 200 generic products (including many complex generic products). Dr. Hariharan obtained his bachelor’s degree in pharmacy at the Banaras Hindu University (BHU) in India and his Ph.D. in Pharmaceutical Sciences at Northeastern University in Boston, Massachusetts.

Dr. Hariharan currently serves on the Board of Depymed, Inc. and the Advisory Board of New Rhein Healthcare, LLC and MAA Laboratories.

Narasimhan Mani, Ph.D., MBA

President

Dr. Narasimhan Mani is an experienced healthcare professional with over 25 years of experience in the pharmaceutical industry. He most recently served as the President & CEO for Kesin Pharma Corporation, a Specialty Pharma company focused on commercializing specialty and brand products. His past roles include serving as the CEO of Xiromed LLC, a Generics and Specialty drug product company, and as the VP of Global Corporate Strategy and BD at Amneal Pharmaceuticals, where he led all the company’s strategic initiatives across Global Strategy, Portfolio Management, Business Development, and Commercial Operations. His previous experiences include being the Corporate Finance and Strategic Planning Leader in the pharmaceutical and medical device sectors at Johnson & Johnson in New Brunswick, NJ. He also worked as a research scientist and product development leader at Forest Laboratories and Par Pharmaceuticals. He continues to be part of the Executives-in-Residence at New Rhein Healthcare Investors, a life-sciences-focused private equity firm. He serves as a Board Member at Corsair Pharma, Inc., one of their portfolio companies.

Dr. Mani’s journey in the pharmaceutical and healthcare sectors began with his B.Pharm (Hons.). from BITS, Pilani, India, which he completed in 1995. His subsequent graduate degrees include an M.S. in Analytical Chemistry from the University of Oklahoma, Norman, in 1998, a Ph.D. in Pharmaceutics from the University of Georgia, Athens, in 2003, and an MBA in Finance and Marketing from Columbia Business School, New York, NY, in 2008. Dr. Mani also received the 2021 Outstanding 50 Asian Americans in Business Award in September 2021.